Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometrial Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
Neoplasms, EndometrialEndometrial Cancer
Interventions
DRUG

topotecan

Trial Locations (24)

4032

GSK Investigational Site, Debrecen

29210

GSK Investigational Site, Columbia

29605

GSK Investigational Site, Greenville

30342

GSK Investigational Site, Atlanta

32804

GSK Investigational Site, Orlando

33143

GSK Investigational Site, Miami

33146

GSK Investigational Site, Coral Gables

33805

GSK Investigational Site, Lakeland

37403

GSK Investigational Site, Chattanooga

37917

GSK Investigational Site, Knoxville

55455

GSK Investigational Site, Minneapolis

60521

GSK Investigational Site, Hinsdale

60612

GSK Investigational Site, Chicago

68510

GSK Investigational Site, Lincoln

70115

GSK Investigational Site, New Orleans

80113

GSK Investigational Site, Engelwood

90033

GSK Investigational Site, Los Angeles

92037

GSK Investigational Site, La Jolla

92663

GSK Investigational Site, Newport Beach

98104

GSK Investigational Site, Seattle

T2N 4N2

GSK Investigational Site, Calgary

K1H 8L6

GSK Investigational Site, Ottawa

H2L 4M1

GSK Investigational Site, Montreal

G1R 2J6

GSK Investigational Site, Québec

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY